Research programme: nitric oxide-releasing compounds - Biolipox/NicOx

Drug Profile

Research programme: nitric oxide-releasing compounds - Biolipox/NicOx

Alternative Names: NCX 1501; NCX 1512

Latest Information Update: 10 Jul 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biolipox; NicOx
  • Class
  • Mechanism of Action Histamine receptor antagonists; Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic rhinitis; Respiratory tract disorders

Most Recent Events

  • 10 Jul 2007 Discontinued - Preclinical for Allergic rhinitis in Europe (unspecified route)
  • 10 Jul 2007 Discontinued - Preclinical for Respiratory tract disorders in Europe (unspecified route)
  • 02 May 2006 No development reported - Preclinical for Allergic rhinitis in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top